- Home
- TVRD vs TLSI Comparison
TVRD vs TLSI Comparison
Compare TVRD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- TLSI
- Stock Information
- Founded
- TVRD 2017
- TLSI 2010
- Country
- TVRD United States
- TLSI United States
- Employees
- TVRD N/A
- TLSI N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- TVRD Health Care
- TLSI Health Care
- Exchange
- TVRD Nasdaq
- TLSI Nasdaq
- Market Cap
- TVRD 246.5M
- TLSI 204.0M
- IPO Year
- TVRD N/A
- TLSI N/A
- Fundamental
- Price
- TVRD $29.44
- TLSI $4.98
- Analyst Decision
- TVRD Strong Buy
- TLSI Strong Buy
- Analyst Count
- TVRD 5
- TLSI 5
- Target Price
- TVRD $59.20
- TLSI $10.90
- AVG Volume (30 Days)
- TVRD 93.5K
- TLSI 153.3K
- Earning Date
- TVRD 08-21-2025
- TLSI 08-13-2025
- Dividend Yield
- TVRD N/A
- TLSI N/A
- EPS Growth
- TVRD N/A
- TLSI N/A
- EPS
- TVRD N/A
- TLSI N/A
- Revenue
- TVRD N/A
- TLSI $32,141,000.00
- Revenue This Year
- TVRD N/A
- TLSI $55.52
- Revenue Next Year
- TVRD N/A
- TLSI $54.76
- P/E Ratio
- TVRD N/A
- TLSI N/A
- Revenue Growth
- TVRD N/A
- TLSI 46.20
- 52 Week Low
- TVRD $8.13
- TLSI $3.50
- 52 Week High
- TVRD $34.31
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- TVRD N/A
- TLSI 45.25
- Support Level
- TVRD N/A
- TLSI $4.85
- Resistance Level
- TVRD N/A
- TLSI $5.11
- Average True Range (ATR)
- TVRD 0.00
- TLSI 0.29
- MACD
- TVRD 0.00
- TLSI -0.03
- Stochastic Oscillator
- TVRD 0.00
- TLSI 23.98
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.